FDA approves Purdue's OxyContin for use in youth aged 11 to 16

The addictive qualities of the powerful pain drug OxyContin have made it controversial, but the FDA has now approved it for youth 11 to 16 after asking maker Purdue Pharma to study its use in that age group. In a post on Thursday, the FDA's Sharon Hertz, director of the Division of Anesthesia, Analgesia, and Addiction Products, wrote that without solid data, doctors too often have to control pediatric pain from cancer and other traumas, by relying "on their own experience to interpret and translate adult data into dosing information for pediatric patients." It will not be the first go-to product but in cases where it is needed, she said doctors now have the info needed to move away from educated guesses. Post | More

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.